Xi’an, China — Xi’an Deli Biochemical Industry Co., Ltd. (“Deli Biochemical”) has released its 2025 business review, highlighting steady progress in international market engagement, reliable product supply, and continued participation in major pharmaceutical exhibitions.
During 2025, Deli Biochemical participated in several major industry exhibitions, including China API Exhibition, CPHI China (Shanghai), and CPHI Worldwide (Frankfurt, Germany). These exhibitions played an important role in strengthening communication with pharmaceutical companies, distributors, and research organizations from both domestic and international markets.
Deli Biochemical at major pharmaceutical exhibitions including CPHI China and CPHI Worldwide in 2025
Throughout 2025, the company maintained stable production and supply by preparing inventory in advance based on customer requirements and project timelines. All customer orders were delivered on schedule, and Deli Biochemical recorded zero customer complaints during the year.
Stable production planning and on-time delivery supported by a strict quality management system
Deli Biochemical focuses on the manufacturing and supply of pharmaceutical excipients and active pharmaceutical ingredients (APIs). Its current product portfolio includes:
Deli Biochemical continues to prioritize regulatory compliance and quality assurance, ensuring all products meet strict pharmaceutical standards. In 2025, the company successfully passed internal and external quality audits, maintained a zero customer complaint record, and strengthened its quality management system to support large-scale production. All products, including HPBCD, SBECD, and pharmaceutical excipients, demonstrate the company's commitment to providing safe, reliable, and high-quality ingredients for pharmaceutical applications.
Looking ahead to 2026, Deli Biochemical plans to further expand its global market presence by participating in China API Exhibition, CPHI China (Shanghai), and CPHI Worldwide (Milan, Italy). The company aims to showcase its latest product developments, including enhanced excipient formulations and innovative pharmaceutical solutions, while strengthening collaboration with both domestic and international partners.
